Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI). RESEARCH DESIGN AND METHODS—In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were randomized to receive pramlintide (six arms: 120, 240, and 360 μg b.i.d. and t.i.d.) or placebo in conjunction with a structured LSI program geared toward weight loss. Of the 4-month evaluable subjects (n = 270), 77% opted to continue preexisting treatment during an 8-month single-blind extension (LSI geared toward weight maintenance). RESULTS—At month 4, mean weight loss from baseline in the pramlintide arms ranged from 3.8 ± 0.7 to 6.1 ± 0.8 kg (2.8 ± 0.8 kg with placebo). By month 12, initial 4-month weight loss was regained in the placebo group but was maintained in all but the 120-μg b.i.d. group. Placebo-corrected weight loss with 120 μg t.i.d. and 360 μg b.i.d. averaged 3.2 ± 1.2 kg (3.1 ± 1.1% body wt) and 3.3 ± 1.1 kg (3.1 ± 1.0% body wt), respectively, at month 4 (both P < 0.01; 4-month evaluable n = 270) and 6.1 ± 2.1 kg (5.6 ± 2.1% body wt) and 7.2 ± 2.3 kg (6.8 ± 2.3% body wt), respectively, at month 12 (both P < 0.01; 12-month evaluable n = 146). At month 12, 40 and 43% of subjects treated with 120 μg t.i.d. and 360 μg b.i.d., respectively, achieved ≥10% weight loss (vs. 12% for placebo). Nausea, the most common adverse event with pramlintide in the 4-month study (9–29% pramlintide vs. 2% placebo), was generally mild to moderate and occurred in <10% of subjects during the extension. CONCLUSIONS—When used over 12 months as an adjunct to LSI, pramlintide treatment, with low-dose three-times-daily or higher-dose two-times-daily regimens, helped obese subjects achieve greater initial weight loss and enhanced long-term maintenance of weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pramlintide is the first synthetic amylin analogue that approved for diabetes management with WL up to 7.9% [86].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, the pramlintide 120 lg three times daily group demonstrated a significant placebocorrected 4.6-mm Hg reduction in SBP and a trend toward improvement with a placebo-corrected 2.6-mm Hg decrease in DBP.”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [215]
In the citing paper
“In one study, 215 placebo-corrected weight loss at month 12 for the pramlintide 120 lg three times daily group averaged 6.1 kg, with higher doses providing little additional benefit.”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · PubMed · Cited by 13,173
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., & Stunkard, A. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050156 · Cited by 794 · cited 2×
“Although the aforementioned factors, and differences in study designs, make it difficult to contextualize pramlintide’s long-term efficacy, it is noteworthy that the proportion of subjects achieving 5 and 10% weight loss at 1 year compares quite favorably to the results reported with oral weight loss medications (15,1…”
BackgroundResultRoth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436 · cited 1×
“In diet-induced obese rats, amylin induced synergistic, fat-specific weight loss when coadministered with leptin, a long-term adiposity signal (22).”
BackgroundSelf-citationHollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307 · cited 1×
“This is consistent with findings from 1-year pramlintide diabetes studies, which also showed durable weight loss over 1 year (12,16,17).”
Self-citationRatner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307 · cited 1×
“This is consistent with findings from 1-year pramlintide diabetes studies, which also showed durable weight loss over 1 year (12,16,17).”
Self-citationEffect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205
Self-citationAronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · cited 1×
“vious studies (9), pramlintide-mediated weight loss was clearly dissociable from the occurrence of nausea.”
BackgroundSelf-citationRoth, J. D., Hughes, H., Kendall, E., Baron, A. D., & Anderson, C. M. (2006) · Endocrinology · doi:10.1210/en.2006-0393 · Cited by 171
Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite Suppressants
Colman, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00013 · Cited by 167 · cited 2×
“To date, efforts to develop obesity pharmacotherapies aimed at reducing food intake and body weight have largely focused on smallmolecule anorectics, an approach that has repeatedly been hampered by safety concerns (1).”
BackgroundSmith, I. G., & Goulder, M. A. (2001) · PubMed · Cited by 149
Research works printed but not linked: 1
- National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report [article online], 1998 (NIH publ. no. 98-4083). Available from http://www.ncbi.nlm.nih.gov/books/bookres.fcgi/obesity/obesity.pdf. Accessed 8 December 2005
Cited by
Items 101–168 of 168
Klein, S., & Romijn, J. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00036-8 · Cited by 16
Thermogenesis and Related Metabolic Targets in Anti-Diabetic Therapy
Arch, J. R. S. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_10 · Cited by 15
Approaches to the pharmacological treatment of obesity
Salem, V., & Bloom, S. R. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.54 · Cited by 15
Comparative Efficiency and Safety of Pharmacological Approaches to the Management of Obesity
Hainer, V. (2011) · Diabetes Care · doi:10.2337/dc11-s255 · Cited by 18
“2 kg in response to a 12-month treatment with synthetic amylin analog pramlintide (360 mg twice daily) was demonstrated in obese and relatively healthy subjects (62).”
BackgroundStein, L. M., McGrath, L. E., Lhamo, R., Koch‐Laskowski, K., Fortin, S. M., Skarbaliene, J., Baader-Pagler, T., Just, R., Hayes, M. R., & Mietlicki‐Baase, E. G. (2021) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00337.2020 · Cited by 13
Hormone-based therapies in the regulation of fuel metabolism and body weight
Kesty, N. C., Roth, J. D., & Maggs, D. G. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.11.1733 · Cited by 13
“(2008) 8(11) 1741 elicit weight loss, however other monotherapy treatments including CCK and leptin have not been successful [35] .”
BackgroundSelf-citationThe evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“Although pramlintide demonstrated efficacy in reducing food intake and promoting weight loss in patients with T2D, the necessity for frequent high-dose injections rendered it undesirable for chronic weight management and it is primarily used as an add-on to mealtime insulin therapy 194,195 .”
Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years
Rose, F., Bloom, S. R., & Tan, T. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1646243 · Cited by 11
“8 kg in the placebo group in non-diabetic patients with BMI between 30 and 50 kg/m(2) [38].”
BackgroundGarber, A. J. (2015) · Endocrine Practice · doi:10.4158/ep14460.ra · Cited by 12
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“While its primary focus has been glycemic control, pramlintide has also been explored for its weight-lowering effects, but with modest efficacy [115].”
Byun, S., Marić, I., Börchers, S., Sotzen, M. R., Olekanma, D. I., Hayes, M. R., & Skibicka, K. P. (2025) · iScience · doi:10.1016/j.isci.2025.112040 · Cited by 11
Pharmacological management of obese child
Petkar, R., & Wright, N. P. (2013) · Archives of Disease in Childhood Education & Practice · doi:10.1136/archdischild-2011-301127 · Cited by 12
Role of amylin in feeding and satiation
Lutz, T. A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110587 · Cited by 12
“…Isaksson et al., 2005; Mack et al., 2007; Olsson et al., 2007); similarly, clinical studies also indicate that the repeated administration of the amylin analogue Pramlintide produced durable actions in patients(Smith et al., 2008), arguing against amylin receptor downregulation or desensitization.”
Long-acting amylin analogue for weight reduction
Gadde, K. M., & Allison, D. B. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01999-1 · Cited by 10
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
“In this study, obese subjects achieved an improvement in weight loss, as well as better maintenance of the reduced body weight, suggesting its potential as a weight loss drug (354).”
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
Zong, L., Zhang, Z., Li, X., Jie, J., Jiang, X., Wang, Z., Liu, W., Shen, X., Feng, X., Huang, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01120 · Cited by 10
Danger-associated metabolites trigger metaflammation: A crowbar in cardiometabolic diseases
Wang, A., Guan, B., Zhang, H., & Xu, H. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106983 · Cited by 10
Intervenções para tratamento da obesidade: revisão sistemática
Nissen, L. P., Vieira, L. H., Bozza, L. F., da Veiga, L. T., Biscaia, B. F. L., Pereira, J. H., & Furlan, L. H. P. (2012) · Revista Brasileira de Medicina de Família e Comunidade · doi:10.5712/rbmfc7(24)472 · Cited by 10
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Bhattachar, S., Tham, L. S., Tidemann‐Miller, B., Ibriga, H., Qu, H., Briere, D. A., Haupt, A., Mather, K. J., & Pratt, E. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70439 · Cited by 10
“8,9 Cagrilintide, a once-weekly peptide that activates calcitonin and amylin receptors with similar potency, resulted in significant weight loss when used as a monotherapy and in combination with semaglutide, a weekly GLP-1 receptor agonist.”
Farmakoterapia otyłości — obecny stan wiedzy
Matyjaszek‐Matuszek, B., Szafraniec, A., & Porada, D. (2018) · Endokrynologia Polska · doi:10.5603/ep.2018.0048 · Cited by 13
Effects of pramlintide on energy intake and food preference in rats given a choice diet
Kern, K. A., DiBrog, A. M., Przybysz, J. T., & Mietlicki‐Baase, E. G. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113541 · Cited by 8
Patch, R. J., Zhang, R., Edavettal, S. C., Macielag, M. J., Eckardt, A. J., Li, J., Rives, M., Edwards, W., Hinke, S. A., Qiu, X., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114330 · Cited by 7
Therapeutic Options for the Prevention of Type 2 Diabetes Mellitus in the Metabolic Syndrome
Lukacova‐Zib, I., & Gopalakrishnan, G. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20204 · Cited by 9
Liberini, C. G., Lhamo, R., Ghidewon, M. Y., Ling, T., Juntereal, N. A., Chen, J. C., Cao, A., Stein, L. M., & Hayes, M. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13591 · Cited by 8
Amylin analogs for the treatment of obesity without diabetes: present and future
Panou, T., Gouveri, E., Popovic, D. S., & Papanas, N. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2409403 · Cited by 5
“Specific time-related data on the effect of pramlintide on weight were used to ascertain the dose-dependent efficacy: weight loss under 120 μg vs. 360 μg was 3.2 kg vs. 3.3 kg in the 4 th month and 6.1 kg vs. 7.2 kg in the 12 th month, respectively [32].”
InfluentialCurrent and Future Medical Treatment of Obesity
Umashanker, D., Igel, L. I., Kumar, R. B., & Aronne, L. J. (2017) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2016.12.008 · Cited by 6
“The most common side effects of pramlintide are hypoglycemia, nausea, followed by anorexia and vomiting.(38)”
BackgroundMethodInfluentialSelf-citationModeling energy intake and body weight effects of a long-acting amylin analogue
Brings, A., Borghardt, J. M., Skarbaliene, J., Baader-Pagler, T., Deryabina, M. A., Rist, W., & Scheuerer, S. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9557-6 · Cited by 7
Pharmacotherapy for obesity: a field in crisis?
Fenske, W., Parker, J. A., & Bloom, S. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.50 · Cited by 4
Targeting the Incretin System in Type 2 Diabetes Mellitus
Potenza, M. V., & Rayfield, E. J. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20112 · Cited by 6
Contemporary approaches to adult Obesity treatment
Meires, J., & Christie, C. (2011) · The Nurse Practitioner · doi:10.1097/01.npr.0000403291.15266.d6 · Cited by 6
Hes, C., Tomlinson, A. J., Michielsen, L., Murdoch, H. J., Soltani, F., Kokoeva, M. V., & Sabatini, P. V. (2025) · eLife · doi:10.7554/elife.106217 · Cited by 9
Treatment options for obesity and potential therapies on the horizon.
Motycka, C. A., Onge, E. S., & Miller, S. A. (2011) · PubMed · Cited by 6
Firing Up Brown Fat with Brain Amylin
López, M., & Nogueiras, R. (2013) · Endocrinology · doi:10.1210/en.2013-1445 · Cited by 4
Klein, S., Fabbrini, E., & Romijn, J. A. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00036-5 · Cited by 8
Pramlintide: profile of an amylin analog
Lebovitz, H. E. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.50 · Cited by 3
Chronic pramlintide decreases feeding via a reduction in meal size in male rats
Kern, K. A., DiBrog, A. M., Kaur, K., Przybysz, J. T., & Mietlicki‐Baase, E. G. (2024) · Peptides · doi:10.1016/j.peptides.2024.171197 · Cited by 5
Liver–pancreas communication in disease and drug development
Jia, Y., Zhu, Q., Pan, Q., Lu, G., & Xiao, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.018 · Cited by 3
“In obese patients, a Phase 2 trial demonstrated sustained weight loss effects: 43% in the treatment group achieved ≥ 10% weight loss, compared to 12% of the placebo group, following 12-month pramlintide treatment as an adjunct to lifestyle intervention 180 .”
From Adipose Dysfunction to Multi-Organ Steatosis: Defining the Metabolic Steatotic Axis
Fajkić, A., Lam, Y. W., Jahić, R., Ćavar, I., Markotić, A., & Belančić, A. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48020178 · Cited by 5
Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics
Tasma, Z., Garelja, M. L., Jamaluddin, A., Alexander, T. I., & Rees, T. A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108846 · Cited by 4
Non‐Insulin Parenteral Therapies
Holst, J. J., Madsbad, S., & Schmitz, O. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch30 · Cited by 4
Future Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Alhalabi, H., Borschel, L., Foll, C. L., Thomas, A., Bally, L., & Thevis, M. (2026) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2026.117418 · Cited by 1
Iannone, L. F., Sebastianelli, G., Santis, F. D., Corrado, M., Marcosano, M., Ornello, R., Grazzi, L., Montisano, D. A., Cesaris, F. D., Munafò, A., et al. (2026) · Cephalalgia · doi:10.1177/03331024261416490 · Cited by 1
“39 The area postrema, an area located outside the blood-brain barrier, is a pivotal area for nausea and expresses amylin-speci fi c receptors.”
Recent developments in GPCR signalling in appetite regulation
Brittain, H. R., & Gorvin, C. M. (2026) · Bioscience Reports · doi:10.1042/bsr20250120 · Cited by 1
“However, the requirement for multiple daily injections of pramlintide [93] led to the development of additional analogues.”
Tratamiento farmacológico contra la obesidad
Londoño-Lemos, M. E. (2012) · Revista Colombiana de Ciencias Químico Farmacéuticas · Cited by 1
New advances and novel approaches in obesity pharmacotherapy
Vaamonde, J. G., Frühbeck, G., & Salvador, J. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.08.003 · Cited by 1
Hes, C., Tomlinson, A. J., Michielsen, L., Murdoch, H. J., Soltani, F., Kokoeva, M. V., & Sabatini, P. V. (2025) · eLife · doi:10.7554/elife.106217.1 · Cited by 2
Of Mice and Men: Translational Research on Amylin Agonism
Roth, J. D., Mack, C. M., Trevaskis, J. L., & Parkes, D. G. (2011) · Wiley eBooks · doi:10.1002/9783527636730.ch14
Pharmacological Management of the Obese Patient
Schumacher, D. (2013) · American Journal of Lifestyle Medicine · doi:10.1177/1559827613504733 · Cited by 2
“This study did not include lifestyle intervention.(87,88) A combination of pramlintide and metreleptin (leptin) resulted in about 13% weight loss, significantly greater than pramlintide or metreleptin treatment alone.”
BackgroundPramlintide in the Management of Obesity
Jones, M. C., DeBellis, H. F., & Barefield, K. L. (2010) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s4021
Jackson, M. J. (2014) · Bangor University Research Portal (Bangor University)
The Gut, Brain, and Peripheral Tissue Connection: Metabolic Disease in the Incretin Era
Kendall, D. M. (2010) · Endocrine Practice · doi:10.1016/s1530-891x(20)42866-6
Advances in Pharmacological Treatment of Pediatric Obesity
Goran, M. I. (2016) · CRC Press eBooks · doi:10.1201/9781315370958-31
Current literature in diabetes
(2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.918
Smith, S. R. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1028-7_15
Self-citationОжирение и современные методы его лечения
Джндоян, З. Т., & Петросян, А. Г. (2022) · Medical Science of Armenia · doi:10.54503/0514-7484-2022-62.3-41
Kern, K. A., DiBrog, A. M., Demieri, E., Przybysz, J. T., Clark, S. D., & Mietlicki‐Baase, E. G. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.115114
Larsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K. (2021) · Figshare · doi:10.6084/m9.figshare.13544378
Larsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K. (2021) · Figshare · doi:10.6084/m9.figshare.13544375
Metabolic Roles of Acyl Coenzyme A-Binding Protein (ACBP)/Diazepam Binding Inhibitor (DBI)
Joseph, A. (2021) · theses.fr (ABES) · doi:10.70675/b045685ezd444z4b46zb0f9z0e726ceac466
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
“In obese non-diabetic adults, a 16-week randomised study and a 12-month multicentre study showed sustained, dose-dependent body-weight reductions of 6%–8% with 120–360 μ g twice or thrice-daily regimens, with enhanced effects when combined with structured lifestyle intervention [182].”
Khan, B. W., Agha, S. A., Qamar, I., Khattak, M. H., Rehman, A., Qazi, T. I., Siddiqui, S. A., Zeeshan, N., Khan, U. Z., Bibi, H., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05809-5
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Antidiabetic medications in the pipeline
Efstathiadou, Z. A., Gogakos, A. I., Divaris, E., Kostopoulos, G., & Makri, E. (2026) · HORMONES · doi:10.1007/s42000-026-00780-5
Pharmacological Therapies of Metabolic Syndrome
Carrillo‐Iregui, A., & Gomez-Meade, C. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2366-8_16
Metadata
- Authors
- Smith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C.
- Affiliations
- Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana
- Weill Cornell Medicine (US)
- Amylin Pharmaceuticals, San Diego, California
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-09-01
- Volume
- 31
- Issue
- 9
- Pages
- 1816-1823
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2518351
- OpenAlex
- W2170571946
- Cited by
- 172
- References
- 19
- Citations by year
- 2026: 11 · 2025: 17 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 15 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 3 · 2013: 11 · 2012: 16
- FWCI
- 10.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- pramlintide, obesity, weight loss, lifestyle intervention, GLP-1 receptor agonists, dose-ranging, weight maintenance, nausea, adverse events, long-term efficacy, weight regain
- MeSH terms
- Adult, Amyloid, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Life Style, Male, Middle Aged, Placebos, Time Factors, Weight Loss, Body Mass Index, Single-Blind Method, Body Size, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.